Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	microfilament motor activity	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.24e-11	38	57	7	GO:0000146
GeneOntologyMolecularFunction	cytoskeletal motor activity	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	4.35e-08	118	57	7	GO:0003774
GeneOntologyMolecularFunction	actin filament binding	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 VILL MYO15A	2.52e-07	227	57	8	GO:0051015
GeneOntologyMolecularFunction	calmodulin binding	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A	2.79e-07	230	57	8	GO:0005516
GeneOntologyMolecularFunction	actin binding	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 VILL MICAL2 MICAL3 MYO15A	9.04e-07	479	57	10	GO:0003779
GeneOntologyMolecularFunction	cytoskeletal protein binding	MAGI1 MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 VILL MICAL2 MICAL3 MYO15A	2.38e-04	1099	57	11	GO:0008092
GeneOntologyMolecularFunction	ATP-dependent activity	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A HSPA4	3.34e-04	614	57	8	GO:0140657
GeneOntologyMolecularFunction	regulatory RNA binding	PIWIL1 PUM2 HNRNPA2B1	7.40e-04	62	57	3	GO:0061980
GeneOntologyMolecularFunction	N6-methyladenosine-containing RNA reader activity	HNRNPA2B1 HNRNPC	8.21e-04	15	57	2	GO:1990247
GeneOntologyBiologicalProcess	muscle filament sliding	MYH2 MYH4 MYH8	8.89e-06	15	57	3	GO:0030049
GeneOntologyBiologicalProcess	actin-myosin filament sliding	MYH2 MYH4 MYH8	1.59e-05	18	57	3	GO:0033275
GeneOntologyBiologicalProcess	actin filament depolymerization	MYH9 VILL MICAL2 MICAL3	3.32e-05	66	57	4	GO:0030042
GeneOntologyBiologicalProcess	protein depolymerization	MYH9 VILL MICAL2 ARHGEF1 MICAL3	4.84e-05	144	57	5	GO:0051261
GeneOntologyBiologicalProcess	actin filament-based movement	MYH2 MYH4 MYH8 MYH9 SCN3A	6.45e-05	153	57	5	GO:0030048
GeneOntologyBiologicalProcess	muscle contraction	MYH1 MYH2 MYH4 MYH8 MYH13 SCN3A ENO1	1.12e-04	400	57	7	GO:0006936
GeneOntologyCellularComponent	myosin filament	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	5.33e-11	25	57	6	GO:0032982
GeneOntologyCellularComponent	myosin II complex	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	1.13e-10	28	57	6	GO:0016460
GeneOntologyCellularComponent	myosin complex	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	2.34e-10	59	57	7	GO:0016459
GeneOntologyCellularComponent	muscle myosin complex	MYH1 MYH2 MYH4 MYH8 MYH13	5.38e-10	16	57	5	GO:0005859
GeneOntologyCellularComponent	actin cytoskeleton	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 VILL MICAL2 DGKH MYO15A HNRNPC	3.70e-07	576	57	11	GO:0015629
GeneOntologyCellularComponent	myofibril	MYH1 MYH2 MYH4 MYH8 MYH13 ENO1	9.75e-05	273	57	6	GO:0030016
GeneOntologyCellularComponent	contractile muscle fiber	MYH1 MYH2 MYH4 MYH8 MYH13 ENO1	1.36e-04	290	57	6	GO:0043292
GeneOntologyCellularComponent	actomyosin contractile ring	MYH2 MYH9	1.52e-04	7	57	2	GO:0005826
GeneOntologyCellularComponent	A band	MYH1 MYH2 ENO1	3.86e-04	52	57	3	GO:0031672
GeneOntologyCellularComponent	sarcomere	MYH1 MYH2 MYH4 MYH8 ENO1	5.82e-04	249	57	5	GO:0030017
GeneOntologyCellularComponent	contractile ring	MYH2 MYH9	6.51e-04	14	57	2	GO:0070938
GeneOntologyCellularComponent	ribonucleoprotein granule	MYH1 PIWIL1 HNRNPA3 PUM2 HNRNPA2B1	1.10e-03	287	57	5	GO:0035770
GeneOntologyCellularComponent	catalytic step 2 spliceosome	HNRNPA3 HNRNPA2B1 HNRNPC	2.36e-03	97	57	3	GO:0071013
MousePheno	abnormal B-1 B cell number	CD22 PIK3CD ARHGEF1 POU2F2 STAT1	5.34e-05	122	47	5	MP:0004976
MousePheno	abnormal B-1 B cell morphology	CD22 PIK3CD ARHGEF1 POU2F2 STAT1	5.55e-05	123	47	5	MP:0004940
Domain	Myosin_N	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	3.02e-12	15	57	6	PF02736
Domain	Myosin_N	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	3.02e-12	15	57	6	IPR004009
Domain	Myosin_tail_1	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	1.11e-11	18	57	6	PF01576
Domain	Myosin_tail	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	1.11e-11	18	57	6	IPR002928
Domain	Myosin-like_IQ_dom	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	1.62e-11	19	57	6	IPR027401
Domain	-	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	1.62e-11	19	57	6	4.10.270.10
Domain	Myosin_head_motor_dom	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.97e-11	38	57	7	IPR001609
Domain	MYOSIN_MOTOR	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.97e-11	38	57	7	PS51456
Domain	Myosin_head	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.97e-11	38	57	7	PF00063
Domain	MYSc	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.97e-11	38	57	7	SM00242
Domain	IQ	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A	4.14e-11	71	57	8	PF00612
Domain	IQ	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A	1.22e-10	81	57	8	SM00015
Domain	IQ_motif_EF-hand-BS	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A	2.88e-10	90	57	8	IPR000048
Domain	IQ	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A	3.76e-10	93	57	8	PS50096
Domain	FAD-bd	MICAL2 MICAL3	1.36e-04	6	57	2	IPR002938
Domain	FAD_binding_3	MICAL2 MICAL3	1.36e-04	6	57	2	PF01494
Domain	P-loop_NTPase	MAGI1 MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 GTPBP1 MYO15A	9.96e-04	848	57	9	IPR027417
Domain	RGS	MYH9 ARHGEF1	6.31e-03	39	57	2	IPR016137
Domain	SAM_2	PPFIBP1 DGKH	7.63e-03	43	57	2	PF07647
Pathway	KEGG_VIRAL_MYOCARDITIS	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	9.65e-08	70	46	6	M12294
Pathway	KEGG_TIGHT_JUNCTION	MAGI1 MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	2.12e-07	132	46	7	M11355
Pubmed	Organization of human and mouse skeletal myosin heavy chain gene clusters is highly conserved.	MYH1 MYH2 MYH4 MYH8 MYH13	5.92e-14	6	57	5	10077619
Pubmed	A fast Myosin super enhancer dictates muscle fiber phenotype through competitive interactions with Myosin genes.	MYH1 MYH2 MYH4 MYH8 MYH13	2.07e-13	7	57	5	35210422
Pubmed	Comparative sequence analysis of the complete human sarcomeric myosin heavy chain family: implications for functional diversity.	MYH1 MYH2 MYH4 MYH13	6.48e-12	4	57	4	10388558
Pubmed	Sequential accumulation of mRNAs encoding different myosin heavy chain isoforms during skeletal muscle development in vivo detected with a recombinant plasmid identified as coding for an adult fast myosin heavy chain from mouse skeletal muscle.	MYH1 MYH2 MYH4 MYH8	3.24e-11	5	57	4	6196357
Pubmed	Developmental pattern of mouse skeletal myosin heavy chain gene transcripts in vivo and in vitro.	MYH1 MYH2 MYH4 MYH8	3.24e-11	5	57	4	3829126
Pubmed	Myosin heavy chain isoforms of the murine masseter muscle during pre- and post-natal development.	MYH1 MYH2 MYH4 MYH8	3.24e-11	5	57	4	12919077
Pubmed	Distinct myogenic programs of embryonic and fetal mouse muscle cells: expression of the perinatal myosin heavy chain isoform in vitro.	MYH1 MYH2 MYH4 MYH8	9.70e-11	6	57	4	1728586
Pubmed	Spatial and temporal changes in myosin heavy chain gene expression in skeletal muscle development.	MYH1 MYH2 MYH4 MYH8	9.70e-11	6	57	4	10588881
Pubmed	Diversity in transcriptional start site selection and alternative splicing affects the 5'-UTR of mouse striated muscle myosin transcripts.	MYH1 MYH2 MYH4 MYH8	2.26e-10	7	57	4	16819597
Pubmed	mTORC1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis.	MAGI1 MYH9 BCLAF1 HNRNPA3 PUM2 GTPBP1 HSPA4 HNRNPA2B1 HNRNPC	6.63e-10	274	57	9	34244482
Pubmed	Modulation of contractile protein gene expression in fetal murine crural muscles: emergence of muscle diversity.	MYH1 MYH2 MYH4 MYH8	2.12e-09	11	57	4	8136524
Pubmed	Functional specialization of beta-arrestin interactions revealed by proteomic analysis.	MYH1 MYH9 NOP56 BCLAF1 HNRNPA3 DGKH HNRNPA2B1 HNRNPC STAT1	2.38e-09	317	57	9	17620599
Pubmed	Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery.	MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 HSPA4 HNRNPA2B1 HNRNPC	3.18e-09	223	57	8	20020773
Pubmed	Transition of myosin heavy chain isoforms in human laryngeal abductors following denervation.	MYH1 MYH2 MYH4	4.17e-09	3	57	3	26059207
Pubmed	Contractile protein gene expression in primary myotubes of embryonic mouse hindlimb muscles.	MYH1 MYH2 MYH4 MYH8	4.58e-09	13	57	4	8404542
Pubmed	Defective excitation-contraction coupling is partially responsible for impaired contractility in hindlimb muscles of Stac3 knockout mice.	MYH1 MYH2 MYH4 MYH8	6.41e-09	14	57	4	27184118
Pubmed	Evaluation of embryonic and perinatal myosin gene mutations and the etiology of congenital idiopathic clubfoot.	MYH1 MYH2 MYH8	1.67e-08	4	57	3	20357587
Pubmed	A human YAC transgene rescues craniofacial and neural tube development in PDGFRalpha knockout mice and uncovers a role for PDGFRalpha in prenatal lung growth.	MYH1 MYH2 MYH4	1.67e-08	4	57	3	11023856
Pubmed	Three linked myosin heavy chain genes clustered within 370 kb of each other show independent transcriptional and post-transcriptional regulation during differentiation of a mouse muscle cell line.	MYH1 MYH4 MYH8	1.67e-08	4	57	3	1985022
Pubmed	Smooth muscle myosin light chain kinase expression in cardiac and skeletal muscle.	MYH1 MYH2 MYH4	1.67e-08	4	57	3	11029314
Pubmed	Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling.	MYH1 MYH2 MYH4	1.67e-08	4	57	3	18417546
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	CDCA2 MYH9 NOP56 MICAL2 ARHGEF1 HNRNPA3 MGA PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1 POLR3A	2.73e-08	1353	57	14	29467282
Pubmed	TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence.	MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 ENO1 HSPA4 HNRNPA2B1 HNRNPC	3.31e-08	430	57	9	38172120
Pubmed	Detection of Gene and Protein Expression in Mouse Embryos and Tissue Sections.	MYH1 MYH2 MYH4	4.16e-08	5	57	3	30737693
Pubmed	FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.	MYH9 NOP56 NOP16 BCLAF1 ARHGEF1 HNRNPA3 ENO1 HNRNPA2B1 HNRNPC STAT1	4.59e-08	601	57	10	33658012
Pubmed	A new role for the calcineurin/NFAT pathway in neonatal myosin heavy chain expression via the NFATc2/MyoD complex during mouse myogenesis.	MYH1 MYH2 MYH4 MYH8	4.64e-08	22	57	4	24301466
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	CDCA2 MYH9 NOP56 BCLAF1 HNRNPA3 HSD17B4 GRM1 GTPBP1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1 POLR3A	5.20e-08	1425	57	14	30948266
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	CDCA2 MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 NOP56 BCLAF1 HNRNPA3 HSD17B4 ENO1 HNRNPA2B1 HNRNPC	6.02e-08	1442	57	14	35575683
Pubmed	Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer.	MYH2 MYH9 NOP56 BCLAF1 PPFIBP1 HNRNPA3 ENO1 HSPA4 HNRNPA2B1 HNRNPC	6.71e-08	626	57	10	33644029
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	NOP56 BBS7 BCLAF1 HNRNPA3 HSD17B4 MGA PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	8.31e-08	1024	57	12	24711643
Pubmed	A hypoplastic model of skeletal muscle development displaying reduced foetal myoblast cell numbers, increased oxidative myofibres and improved specific tension capacity.	MYH1 MYH2 MYH4	8.32e-08	6	57	3	20417199
Pubmed	A role for Insulin-like growth factor 2 in specification of the fast skeletal muscle fibre.	MYH1 MYH2 MYH4	8.32e-08	6	57	3	17559643
Pubmed	∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 HSD17B4 ENO1 HSPA4 HNRNPC	9.11e-08	647	57	10	26618866
Pubmed	SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.	MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 PUM2 HSD17B4 PLOD1 HNRNPA2B1 HNRNPC	1.02e-07	655	57	10	35819319
Pubmed	Integrative analysis of the ubiquitin proteome isolated using Tandem Ubiquitin Binding Entities (TUBEs).	NOP56 HNRNPA3 HNRNPA2B1 HNRNPC	1.29e-07	28	57	4	22178446
Pubmed	ANKK1 is found in myogenic precursors and muscle fibers subtypes with glycolytic metabolism.	MYH1 MYH2 MYH4	1.45e-07	7	57	3	29758057
Pubmed	New interaction partners for Nek4.1 and Nek4.2 isoforms: from the DNA damage response to RNA splicing.	MYH9 NOP56 BCLAF1 SETBP1 HNRNPA3 ENO1 HNRNPA2B1 FAM83C HNRNPC	1.48e-07	513	57	9	25798074
Pubmed	Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.	BCLAF1 HNRNPA3 ENO1 ADARB1 HSPA4 HNRNPA2B1 HNRNPC	1.51e-07	244	57	7	30349055
Pubmed	BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression.	MYH9 NOP56 ARHGEF1 HNRNPA3 PUM2 HSD17B4 GTPBP1 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	1.62e-07	1318	57	13	30463901
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	MAGI1 MYH9 NOP56 BCLAF1 PPFIBP1 MICAL3 ENO1 HSPA4 HNRNPA2B1 STAT1	2.09e-07	708	57	10	39231216
Pubmed	Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.	MYH1 MYH2 MYH4	2.32e-07	8	57	3	26993635
Pubmed	Genes for skeletal muscle myosin heavy chains are clustered and are not located on the same mouse chromosome as a cardiac myosin heavy chain gene.	MYH1 MYH4 MYH8	2.32e-07	8	57	3	3864153
Pubmed	Cell lineage- and expression-based inference of the roles of forkhead box transcription factor Foxc2 in craniofacial development.	MYH1 MYH2 MYH4	2.32e-07	8	57	3	33667029
Pubmed	A Tcf4-positive mesodermal population provides a prepattern for vertebrate limb muscle patterning.	MYH1 MYH2 MYH4	2.32e-07	8	57	3	14667415
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	ESCO2 MYH9 MYH13 NOP56 NOP16 BCLAF1 PEG3 GTPBP1 PLOD1 ENO1 HNRNPA2B1 HNRNPC STAT1	2.55e-07	1371	57	13	36244648
Pubmed	Myosin heavy chain-embryonic regulates skeletal muscle differentiation during mammalian development.	MYH1 MYH2 MYH4 MYH8	2.56e-07	33	57	4	32094117
Pubmed	Prohibitin 1 regulates tumor cell apoptosis via the interaction with X-linked inhibitor of apoptosis protein.	MYH9 NOP16 HNRNPA3 LPGAT1 GTPBP1 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC	2.60e-07	725	57	10	27025967
Pubmed	GASP-2 overexpressing mice exhibit a hypermuscular phenotype with contrasting molecular effects compared to GASP-1 transgenics.	MYH1 MYH2 MYH4	3.48e-07	9	57	3	31960486
Pubmed	Proteomic and biochemical analysis of 14-3-3-binding proteins during C2-ceramide-induced apoptosis.	MYH2 MYH9 MYH13 HNRNPA2B1 HNRNPC	3.49e-07	88	57	5	20618440
Pubmed	During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation.	MYH1 MYH4 MYH8	4.97e-07	10	57	3	19506036
Pubmed	Acceleration of somitic myogenesis in embryos of myogenin promoter-MRF4 transgenic mice.	MYH1 MYH2 MYH8	4.97e-07	10	57	3	8950513
Pubmed	Temporal regulation of the Mediator complex during muscle proliferation, differentiation, regeneration, aging, and disease.	MYH1 MYH2 MYH4 MYH8	5.11e-07	39	57	4	38690566
Pubmed	A New Cellular Interactome of SARS-CoV-2 Nucleocapsid Protein and Its Biological Implications.	HNRNPA3 ENO1 HSPA4 HNRNPA2B1 HNRNPC	5.12e-07	95	57	5	37211047
Pubmed	MYC multimers shield stalled replication forks from RNA polymerase.	CDCA2 MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC	5.19e-07	989	57	11	36424410
Pubmed	The dynamic interactome of human Aha1 upon Y223 phosphorylation.	MYH2 BCLAF1 ARHGEF1 ENO1 HNRNPA2B1	5.39e-07	96	57	5	26693507
Pubmed	TRIM37 Mediates Chemoresistance and Maintenance of Stemness in Pancreatic Cancer Cells via Ubiquitination of PTEN and Activation of the AKT-GSK-3β-β-Catenin Signaling Pathway.	MYH2 MYH4 MYH9 MYH13 ENO1 HNRNPA2B1 HNRNPC	6.76e-07	305	57	7	33194618
Pubmed	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.	MAGI1 MYH9 NOP16 MICAL2 BCLAF1 HNRNPA3 MGA ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	6.81e-07	1247	57	12	27684187
Pubmed	Extracellular matrix protein composition dynamically changes during murine forelimb development.	MYH1 MYH2 MYH4	6.82e-07	11	57	3	38303699
Pubmed	Deletion of the protein kinase A/protein kinase G target SMTNL1 promotes an exercise-adapted phenotype in vascular smooth muscle.	MYH1 MYH2 MYH4	6.82e-07	11	57	3	18310078
Pubmed	The histone code reader Spin1 controls skeletal muscle development.	MYH1 MYH2 MYH4	6.82e-07	11	57	3	29168801
Pubmed	Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers.	MYH1 MYH2 MYH4	6.82e-07	11	57	3	16024798
Pubmed	High-sensitivity profiling of SARS-CoV-2 noncoding region-host protein interactome reveals the potential regulatory role of negative-sense viral RNA.	NOP56 HNRNPA3 HSD17B4 GTPBP1 PLOD1 ADARB1 HNRNPA2B1 HNRNPC	9.54e-07	469	57	8	37314180
Pubmed	HOXA5 plays tissue-specific roles in the developing respiratory system.	MYH1 MYH2 MYH4 MYH8	1.00e-06	46	57	4	28827394
Pubmed	The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4.	MYH9 HNRNPA3 ENO1 HSPA4 HNRNPA2B1	1.06e-06	110	57	5	18307411
Pubmed	Two-Dimensional Fractionation Method for Proteome-Wide Cross-Linking Mass Spectrometry Analysis.	MYH9 MYH13 NOP56 BCLAF1 HNRNPA3 ENO1 HSPA4 HNRNPA2B1 HNRNPC POLR3A	1.07e-06	847	57	10	35235311
Pubmed	The inhibition of differentiation caused by TGFbeta in fetal myoblasts is dependent upon selective expression of PKCtheta: a possible molecular basis for myoblast diversification during limb histogenesis.	MYH1 MYH2 MYH8	1.18e-06	13	57	3	8948582
Pubmed	Loss of Prox1 in striated muscle causes slow to fast skeletal muscle fiber conversion and dilated cardiomyopathy.	MYH1 MYH2 MYH4	1.50e-06	14	57	3	24938781
Pubmed	Myopathy associated LDB3 mutation causes Z-disc disassembly and protein aggregation through PKCα and TSC2-mTOR downregulation.	MYH1 MYH2 MYH4	1.50e-06	14	57	3	33742095
Pubmed	Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.	MYH1 MYH4 NOP56 HNRNPA3 ENO1 HSPA4	1.66e-06	220	57	6	24550385
Pubmed	Six homeoproteins and a Iinc-RNA at the fast MYH locus lock fast myofiber terminal phenotype.	MYH1 MYH2 MYH4	1.87e-06	15	57	3	24852826
Pubmed	Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass.	NOP56 HNRNPA3 HSD17B4 HNRNPA2B1 HNRNPC	1.92e-06	124	57	5	23000965
Pubmed	RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.	MYH9 NOP56 BCLAF1 HNRNPA3 PUM2 GTPBP1 PLOD1 HNRNPA2B1 HNRNPC	2.27e-06	713	57	9	29802200
Pubmed	Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.	NOP56 BCLAF1 HNRNPA3 PUM2 HSD17B4 ENO1 HSPA4 HNRNPA2B1 HNRNPC	2.30e-06	714	57	9	28302793
Pubmed	MusTRD can regulate postnatal fiber-specific expression.	MYH1 MYH2 MYH4	2.30e-06	16	57	3	16494860
Pubmed	A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance.	MYH1 MYH2 MYH4	2.30e-06	16	57	3	19922871
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	MYH13 SLC15A1 BCLAF1 OVCH1 ADARB1 HNRNPC	2.37e-06	234	57	6	36243803
Pubmed	Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones.	MYH9 NOP56 NOP16 PPFIBP1 ARHGEF1 HNRNPA3 HSD17B4 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC	2.54e-06	1415	57	12	28515276
Pubmed	Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.	MYH9 HNRNPA3 HNRNPA2B1 HNRNPC	2.57e-06	58	57	4	30009671
Pubmed	Genesis of muscle fiber-type diversity during mouse embryogenesis relies on Six1 and Six4 gene expression.	MYH1 MYH2 MYH4 MYH8	2.57e-06	58	57	4	21884692
Pubmed	Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages.	NR1H4 STAT1	2.64e-06	2	57	2	19393742
Pubmed	ESCO2 promotes hypopharyngeal carcinoma progression in a STAT1-dependent manner.	ESCO2 STAT1	2.64e-06	2	57	2	37968576
Pubmed	Myosin heavy chains IIa and IId are functionally distinct in the mouse.	MYH1 MYH2	2.64e-06	2	57	2	9585413
Pubmed	Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts.	HNRNPA2B1 HNRNPC	2.64e-06	2	57	2	2557628
Pubmed	Analysis of mouse conceptuses with uniparental duplication/deficiency for distal chromosome 12: comparison with chromosome 12 uniparental disomy and implications for genomic imprinting.	MYH1 MYH2	2.64e-06	2	57	2	16575183
Pubmed	Five skeletal myosin heavy chain genes are organized as a multigene complex in the human genome.	MYH4 MYH8	2.64e-06	2	57	2	8518795
Pubmed	Type IIx myosin heavy chain transcripts are expressed in type IIb fibers of human skeletal muscle.	MYH1 MYH2	2.64e-06	2	57	2	7545970
Pubmed	Growth and muscle defects in mice lacking adult myosin heavy chain genes.	MYH1 MYH4	2.64e-06	2	57	2	9382868
Pubmed	Postnatal myosin heavy chain isoform expression in normal mice and mice null for IIb or IId myosin heavy chains.	MYH1 MYH4	2.64e-06	2	57	2	11150240
Pubmed	Myosin heavy chain composition of the human genioglossus muscle.	MYH1 MYH2	2.64e-06	2	57	2	22337492
Pubmed	Temporal spatial expression and function of non-muscle myosin II isoforms IIA and IIB in scar remodeling.	MYH2 MYH4	2.64e-06	2	57	2	21102503
Pubmed	Myosin-IIA and ICAM-1 regulate the interchange between two distinct modes of T cell migration.	MYH2 MYH9	2.64e-06	2	57	2	19201857
Pubmed	Different pathways regulate expression of the skeletal myosin heavy chain genes.	MYH1 MYH2	2.64e-06	2	57	2	11551968
Pubmed	Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice.	MYH1 MYH4	2.64e-06	2	57	2	11744674
Pubmed	Optimized fragmentation schemes and data analysis strategies for proteome-wide cross-link identification.	MYH1 MYH9 DDAH1 BCLAF1 ENO1 HSPA4 HNRNPA2B1 HNRNPC	2.64e-06	538	57	8	28524877
Pubmed	Slow and fast fiber isoform gene expression is systematically altered in skeletal muscle of the Sox6 mutant, p100H.	MYH2 MYH4 MYH8	2.79e-06	17	57	3	16124007
Pubmed	IKKα and alternative NF-κB regulate PGC-1β to promote oxidative muscle metabolism.	MYH1 MYH2 MYH4	2.79e-06	17	57	3	22351927
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	MYH9 DDAH1 MICAL2 BCLAF1 ARHGEF1 HNRNPA3 MICAL3 GRM1 GTPBP1 HSPA4 HNRNPA2B1 HNRNPC	2.85e-06	1431	57	12	37142655
Pubmed	Arginine methylation and ubiquitylation crosstalk controls DNA end-resection and homologous recombination repair.	MYH9 BCLAF1 HNRNPA3 MGA ENO1 HSPA4 HNRNPA2B1 HNRNPC	3.15e-06	551	57	8	34728620
Pubmed	Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis.	MYH1 MYH2 MYH4	3.35e-06	18	57	3	25753484
Pubmed	The Nuclear SUMO-Targeted Ubiquitin Quality Control Network Regulates the Dynamics of Cytoplasmic Stress Granules.	NOP56 HNRNPA3 HNRNPA2B1 HNRNPC	4.07e-06	65	57	4	32521226
Interaction	RSPH6A interactions	MYH1 MYH2 MYH4 MYH8 MYH13	3.95e-08	34	57	5	int:RSPH6A
Interaction	GLDC interactions	MAGI1 MYH9 BCLAF1 HNRNPA3 PUM2 GTPBP1 HSPA4 HNRNPA2B1 HNRNPC	2.71e-07	321	57	9	int:GLDC
Interaction	TSPAN33 interactions	MYH1 MYH2 MYH4 MYH8 MYH13	1.10e-06	65	57	5	int:TSPAN33
Interaction	MIR199A2 interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	2.40e-06	76	57	5	int:MIR199A2
Interaction	GAPDH interactions	CDCA2 MYH9 HNRNPA3 POU2F2 HSD17B4 GRM1 ENO1 HSPA4 HNRNPA2B1 HNRNPC NR1H4	2.91e-06	686	57	11	int:GAPDH
Interaction	BCAP31 interactions	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 NOP56 MICAL2 LPGAT1 ENO1	3.07e-06	554	57	10	int:BCAP31
Interaction	LACTB2 interactions	MYH1 MYH4 DDAH1 MYH13 ENO1	3.50e-06	82	57	5	int:LACTB2
Interaction	MIR221 interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	5.54e-06	90	57	5	int:MIR221
Interaction	MIRLET7F1 interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	6.85e-06	94	57	5	int:MIRLET7F1
Interaction	MIRLET7F2 interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	8.00e-06	97	57	5	int:MIRLET7F2
Interaction	MIRLET7B interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	9.74e-06	101	57	5	int:MIRLET7B
Interaction	MIRLET7A3 interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	1.02e-05	102	57	5	int:MIRLET7A3
Interaction	SBDS interactions	MYH1 MYH2 MYH4 MYH8 MYH13 HNRNPA2B1	1.20e-05	181	57	6	int:SBDS
Interaction	MIRLET7A1 interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	1.35e-05	108	57	5	int:MIRLET7A1
Interaction	TARDBP interactions	MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 ENO1 HSPA4 HNRNPA2B1 HNRNPC	1.41e-05	520	57	9	int:TARDBP
Interaction	LZTR1 interactions	MYH1 MYH4 MYH8 MYH13 STAT1	1.54e-05	111	57	5	int:LZTR1
Interaction	CDK3 interactions	MYH1 MYH2 MYH8 MYH13 HSPA4	1.76e-05	114	57	5	int:CDK3
Interaction	RC3H1 interactions	NOP56 NOP16 BCLAF1 HNRNPA3 HSD17B4 MGA PLOD1 HSPA4 HNRNPA2B1 HNRNPC	1.78e-05	677	57	10	int:RC3H1
Interaction	SMC5 interactions	CDCA2 MYH1 MYH4 MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 MGA ENO1 HNRNPA2B1 HNRNPC	1.86e-05	1000	57	12	int:SMC5
Interaction	MIRLET7G interactions	HNRNPA3 PUM2 PLOD1 ADARB1 HNRNPA2B1	1.99e-05	117	57	5	int:MIRLET7G
Interaction	RNF113A interactions	MYH9 NOP56 NOP16 BCLAF1 HNRNPA3 PUM2 HSD17B4 PLOD1 HNRNPA2B1 HNRNPC	2.14e-05	692	57	10	int:RNF113A
Interaction	MCM5 interactions	ESCO2 MYH9 ARHGEF1 HNRNPA3 ENO1 HNRNPA2B1 HNRNPC STAT1	2.25e-05	420	57	8	int:MCM5
Interaction	DNAH8 interactions	ENO1 HSPA4 HNRNPA2B1	2.36e-05	20	57	3	int:DNAH8
Interaction	NR2C2 interactions	MYH9 NOP56 ARHGEF1 HNRNPA3 PUM2 PELI1 HSD17B4 GTPBP1 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	2.65e-05	1403	57	14	int:NR2C2
Interaction	NEK4 interactions	MYH9 NOP56 BCLAF1 SETBP1 HNRNPA3 ENO1 HNRNPA2B1 FAM83C HNRNPC	3.43e-05	582	57	9	int:NEK4
Interaction	CAND1 interactions	NOP56 NOP16 BCLAF1 HNRNPA3 GTPBP1 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	3.49e-05	894	57	11	int:CAND1
Interaction	PRKAG2 interactions	MYH1 MYH2 MYH4 MYH8	4.09e-05	68	57	4	int:PRKAG2
Interaction	SLC39A3 interactions	MYH1 MYH2 MYH4 MYH8	4.59e-05	70	57	4	int:SLC39A3
Interaction	G6PC2 interactions	HNRNPA3 HNRNPA2B1	4.70e-05	4	57	2	int:G6PC2
Interaction	WDR5 interactions	MYH9 NOP16 BCLAF1 SETBP1 HNRNPA3 HSD17B4 GTPBP1 MGA ENO1 HSPA4 HNRNPA2B1 HNRNPC	4.79e-05	1101	57	12	int:WDR5
Interaction	COPS5 interactions	MYH9 NOP56 NOP16 HNRNPA3 PUM2 GTPBP1 PLOD1 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	4.83e-05	1102	57	12	int:COPS5
Interaction	PRMT1 interactions	MYH9 NOP56 BCLAF1 HNRNPA3 MGA ENO1 HSPA4 HNRNPA2B1 HNRNPC NR1H4 STAT1	4.95e-05	929	57	11	int:PRMT1
Interaction	HDAC1 interactions	ESCO2 MYH1 MYH2 MYH4 MYH8 MYH9 MGA ENO1 HSPA4 HNRNPC STAT1 POLR3A	5.09e-05	1108	57	12	int:HDAC1
Interaction	S100A4 interactions	ESCO2 MYH2 MYH4 MYH9 PPFIBP1	5.39e-05	144	57	5	int:S100A4
Interaction	BGLT3 interactions	MYH9 HNRNPA3 HSPA4 HNRNPA2B1	6.02e-05	75	57	4	int:BGLT3
Interaction	MIR7-3 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	6.34e-05	76	57	4	int:MIR7-3
Interaction	TRIM37 interactions	MYH2 MYH4 MYH9 MYH13 BBS7 MGA ENO1 HNRNPA2B1 HNRNPC	6.34e-05	630	57	9	int:TRIM37
Interaction	MIR9-2 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	6.67e-05	77	57	4	int:MIR9-2
Interaction	MIR98 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	7.02e-05	78	57	4	int:MIR98
Interaction	ISG15 interactions	MYH9 BCLAF1 HNRNPA3 PLOD1 ENO1 HSPA4 HNRNPA2B1 STAT1	7.09e-05	494	57	8	int:ISG15
Interaction	BTF3 interactions	MYH2 MYH9 NOP56 BCLAF1 PPFIBP1 HNRNPA3 ENO1 HSPA4 HNRNPA2B1 HNRNPC	7.22e-05	799	57	10	int:BTF3
Interaction	MIR222 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	7.38e-05	79	57	4	int:MIR222
Interaction	MIR206 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	7.38e-05	79	57	4	int:MIR206
Interaction	MIR1-2 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	7.38e-05	79	57	4	int:MIR1-2
Interaction	MIR143 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	7.75e-05	80	57	4	int:MIR143
Interaction	OR9Q2 interactions	MYH9 HNRNPA3	7.82e-05	5	57	2	int:OR9Q2
Interaction	STK4 interactions	MYH1 MYH2 MYH8 MYH13 HSPA4	8.63e-05	159	57	5	int:STK4
Interaction	MYCN interactions	MYH9 NOP56 NOP16 MICAL2 BCLAF1 HNRNPA3 GTPBP1 PLOD1 ENO1 ADARB1 HSPA4 HNRNPA2B1 HNRNPC	9.35e-05	1373	57	13	int:MYCN
Interaction	MIR7-2 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	9.38e-05	84	57	4	int:MIR7-2
Interaction	TPM1 interactions	MYH1 MYH2 MYH4 MYH8 MYH9 STAT1	9.69e-05	263	57	6	int:TPM1
Interaction	WEE2-AS1 interactions	MYH9 BCLAF1 GTPBP1 HNRNPA2B1 HNRNPC	9.70e-05	163	57	5	int:WEE2-AS1
Interaction	MIR17 interactions	HNRNPA3 PUM2 PLOD1 HNRNPA2B1	9.82e-05	85	57	4	int:MIR17
Interaction	MIR9-1 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	9.82e-05	85	57	4	int:MIR9-1
Interaction	MIR141 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	1.12e-04	88	57	4	int:MIR141
Interaction	NHLH1 interactions	CDCA2 NOP56 NOP16 MGA	1.12e-04	88	57	4	int:NHLH1
Interaction	ASAH2 interactions	MYH1 MYH4	1.17e-04	6	57	2	int:ASAH2
Interaction	MIR92A2 interactions	HNRNPA3 PUM2 ADARB1 HNRNPA2B1	1.23e-04	90	57	4	int:MIR92A2
Interaction	KIF23 interactions	MYH9 NOP56 NOP16 MICAL2 BCLAF1 HNRNPA3 MICAL3 HSD17B4 ENO1 HNRNPA2B1 HNRNPC	1.26e-04	1031	57	11	int:KIF23
Interaction	MIR214 interactions	HNRNPA3 PUM2 PLOD1 HNRNPA2B1	1.39e-04	93	57	4	int:MIR214
Interaction	DNAH6 interactions	MYH9 HNRNPA3 HNRNPA2B1	1.43e-04	36	57	3	int:DNAH6
Interaction	KCNA3 interactions	MAGI1 MYH9 NOP56 BCLAF1 PPFIBP1 MICAL3 ENO1 HSPA4 HNRNPA2B1 STAT1	1.47e-04	871	57	10	int:KCNA3
Interaction	CEBPB interactions	MYH9 NOP56 NOP16 BCLAF1 ARHGEF1 HNRNPA3 PUM2 ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1 POLR3A	1.54e-04	1443	57	13	int:CEBPB
Interaction	MIRLET7A2 interactions	HNRNPA3 PUM2 PLOD1 HNRNPA2B1	1.57e-04	96	57	4	int:MIRLET7A2
Interaction	STK3 interactions	MYH1 MYH2 MYH8 MYH13 NOP16	1.59e-04	181	57	5	int:STK3
Interaction	EFTUD2 interactions	MYH9 NOP56 NOP16 PPFIBP1 ARHGEF1 HNRNPA3 HSD17B4 PLOD1 ENO1 ADARB1 HSPA4 HNRNPA2B1 HNRNPC	1.61e-04	1449	57	13	int:EFTUD2
Interaction	MIRLET7C interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	1.64e-04	97	57	4	int:MIRLET7C
Interaction	MIR363 interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	1.64e-04	97	57	4	int:MIR363
Interaction	METTL14 interactions	MYH9 NOP56 HNRNPA3 PUM2 ENO1 HSPA4 HNRNPA2B1 HNRNPC	1.64e-04	558	57	8	int:METTL14
Interaction	RBX1 interactions	MYH9 BCLAF1 HNRNPA3 ENO1 ADARB1 HSPA4 HNRNPA2B1 HNRNPC	1.64e-04	558	57	8	int:RBX1
Interaction	ZSCAN5A interactions	MYH1 MYH4 MYH8	1.69e-04	38	57	3	int:ZSCAN5A
Interaction	MIR128-2 interactions	HNRNPA3 PUM2 PLOD1 HNRNPA2B1	1.77e-04	99	57	4	int:MIR128-2
Interaction	AHSA1 interactions	MYH2 BCLAF1 ARHGEF1 ENO1 HNRNPA2B1 STAT1	1.78e-04	294	57	6	int:AHSA1
Interaction	ABTB2 interactions	MYH1 MYH2 MYH4 MYH8	1.91e-04	101	57	4	int:ABTB2
Interaction	MYLK2 interactions	NOP56 HNRNPA3 HSPA4 HNRNPC	1.91e-04	101	57	4	int:MYLK2
Interaction	OBSL1 interactions	DDAH1 NOP56 BCLAF1 PPFIBP1 HNRNPA3 MGA PLOD1 ENO1 HNRNPA2B1 HNRNPC	1.95e-04	902	57	10	int:OBSL1
Interaction	MIR15B interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	2.06e-04	103	57	4	int:MIR15B
Interaction	ARRB1 interactions	MYH1 MYH9 BCLAF1 HNRNPA3 DGKH GRM1	2.13e-04	304	57	6	int:ARRB1
Interaction	MIR34A interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	2.14e-04	104	57	4	int:MIR34A
Interaction	C2orf78 interactions	HNRNPA3 HNRNPA2B1	2.18e-04	8	57	2	int:C2orf78
Interaction	MIRLET7E interactions	HNRNPA3 PUM2 PLOD1 HNRNPA2B1	2.30e-04	106	57	4	int:MIRLET7E
Interaction	LATS1 interactions	MAGI1 MYH1 MYH2 MYH4 MYH8 MYH13 MGA	2.32e-04	440	57	7	int:LATS1
Interaction	GSPT2 interactions	BCLAF1 PUM2 HNRNPC STAT1	2.39e-04	107	57	4	int:GSPT2
Interaction	AURKC interactions	MYH1 MYH4 MYH8	2.44e-04	43	57	3	int:AURKC
Interaction	UHRF2 interactions	BCLAF1 PEG3 HNRNPA3 MGA HNRNPA2B1	2.52e-04	200	57	5	int:UHRF2
Interaction	H2BC9 interactions	CDCA2 MYH2 MYH9 SETBP1 ENO1 ADARB1 HNRNPA2B1	2.52e-04	446	57	7	int:H2BC9
Interaction	AGR2 interactions	MAGI1 MYH9 NOP56 HNRNPA3 LPGAT1 MYO15A ENO1 HSPA4 HNRNPA2B1 HNRNPC	2.59e-04	934	57	10	int:AGR2
Interaction	PHB1 interactions	MYH9 NOP16 HNRNPA3 LPGAT1 GTPBP1 PLOD1 ENO1 BAIAP3 HSPA4 HNRNPA2B1 HNRNPC	2.65e-04	1123	57	11	int:PHB1
Interaction	MIR34B interactions	HNRNPA3 PLOD1 ADARB1 HNRNPA2B1	2.66e-04	110	57	4	int:MIR34B
Interaction	ARRB2 interactions	MYH9 NOP56 BCLAF1 GRM1 HNRNPA2B1 HNRNPC STAT1	2.81e-04	454	57	7	int:ARRB2
Interaction	FGD5 interactions	MYH4 MYH9 HSD17B4 ENO1 HSPA4	2.96e-04	207	57	5	int:FGD5
Interaction	HSF1 interactions	MYH13 NOP56 BCLAF1 MGA ENO1 HSPA4 HNRNPA2B1 STAT1	2.97e-04	609	57	8	int:HSF1
Interaction	SMARCA4 interactions	NOP56 ADARB1 HNRNPA2B1 HNRNPC NR1H4 STAT1 POLR3A	3.12e-04	462	57	7	int:SMARCA4
Interaction	TSSK6 interactions	BCLAF1 HSPA4 POLR3A	3.18e-04	47	57	3	int:TSSK6
Interaction	NFX1 interactions	MYH9 BCLAF1 HNRNPA3 HSD17B4 GTPBP1 HSPA4 HNRNPA2B1	3.29e-04	466	57	7	int:NFX1
Interaction	PTMA interactions	MYH4 MYH9 HNRNPA3 ENO1 HNRNPA2B1	3.30e-04	212	57	5	int:PTMA
Interaction	COL6A1 interactions	HSD17B4 PLOD1 HSPA4 STAT1	3.36e-04	117	57	4	int:COL6A1
Interaction	PRNP interactions	MAGI1 VILL PPFIBP1 ICA1 HNRNPA3 MGA ENO1 HSPA4 HNRNPA2B1 HNRNPC STAT1	3.45e-04	1158	57	11	int:PRNP
Interaction	SCARNA22 interactions	NOP56 HNRNPA3 HSD17B4 HNRNPC	3.47e-04	118	57	4	int:SCARNA22
Interaction	SF3A1 interactions	MYH9 BCLAF1 HNRNPA3 ENO1 ADARB1 HNRNPA2B1 HNRNPC	3.51e-04	471	57	7	int:SF3A1
Interaction	SNRNP70 interactions	MYH9 NOP56 BCLAF1 HNRNPA3 PUM2 GTPBP1 PLOD1 ADARB1 HNRNPA2B1 HNRNPC	3.92e-04	984	57	10	int:SNRNP70
Cytoband	17p13.1	MYH1 MYH2 MYH4 MYH8	1.47e-05	118	57	4	17p13.1
Cytoband	Ensembl 112 genes in cytogenetic band chr17p13	MYH1 MYH2 MYH4 MYH8 MYH13	7.17e-05	346	57	5	chr17p13
Cytoband	1p36.2	PIK3CD ENO1	1.17e-04	13	57	2	1p36.2
Cytoband	22q13.1	MYH9 FAM227A GTPBP1	1.67e-04	85	57	3	22q13.1
GeneFamily	Myosin heavy chains	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	5.33e-13	15	42	6	1098
Coexpression	HUMMERICH_BENIGN_SKIN_TUMOR_DN	MYH1 MYH2 MYH4 MYH8	9.48e-08	20	57	4	M1123
Coexpression	HUMMERICH_BENIGN_SKIN_TUMOR_DN	MYH1 MYH2 MYH4 MYH8	1.17e-07	21	57	4	MM1102
Coexpression	GSE28726_ACT_CD4_TCELL_VS_ACT_VA24NEG_NKTCELL_UP	NOP56 HNRNPA3 MGA ENO1 ADARB1 HNRNPC	4.81e-06	200	57	6	M8305
Coexpression	GSE1460_DP_VS_CD4_THYMOCYTE_DN	MICAL2 PIK3CD SCN3A PLOD1 ADARB1 STAT1	4.81e-06	200	57	6	M3454
Coexpression	PUJANA_ATM_PCC_NETWORK	NOP56 NOP16 SLC15A1 CD22 PIK3CD ARHGEF1 HNRNPA3 LPGAT1 POU2F2 HSPA4 HNRNPA2B1 HNRNPC STAT1	7.03e-06	1394	57	13	M9585
Coexpression	WANG_TUMOR_INVASIVENESS_UP	PIK3CD HSD17B4 PLOD1 ENO1 HSPA4 HNRNPA2B1 STAT1	1.93e-05	384	57	7	M1865
Coexpression	WANG_TUMOR_INVASIVENESS_UP	PIK3CD HSD17B4 PLOD1 ENO1 HSPA4 HNRNPA2B1 STAT1	2.59e-05	402	57	7	MM1248
Coexpression	GSE37301_HEMATOPOIETIC_STEM_CELL_VS_RAG2_KO_NK_CELL_UP	MYH9 PIK3CD ARHGEF1 BAIAP3 STAT1	3.85e-05	174	57	5	M8885
Coexpression	GSE16385_MONOCYTE_VS_12H_ROSIGLITAZONE_IFNG_TNF_TREATED_MACROPHAGE_UP	ESCO2 MAGI1 PIK3CD HSD17B4 GTPBP1	7.12e-05	198	57	5	M7902
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	MYH9 PIK3CD BCLAF1 ARHGEF1 HNRNPA3 LPGAT1 PUM2 POU2F2 ENO1 ADARB1 HNRNPA2B1 STAT1	7.18e-05	1492	57	12	M40023
Coexpression	HALLMARK_MYC_TARGETS_V1	NOP56 NOP16 HNRNPA3 HNRNPA2B1 HNRNPC	7.46e-05	200	57	5	M5926
Coexpression	HALLMARK_MYOGENESIS	MYH1 MYH2 MYH4 MYH8 MYH9	7.46e-05	200	57	5	M5909
Coexpression	HOSHIDA_LIVER_CANCER_SUBCLASS_S2	BCLAF1 PEG3 HNRNPA2B1 HNRNPC	1.16e-04	115	57	4	M7995
Coexpression	SCHLOSSER_SERUM_RESPONSE_DN	PIK3CD BCLAF1 HNRNPA3 LPGAT1 ADARB1 HSPA4 HNRNPA2B1 STAT1	1.36e-04	705	57	8	M1410
Coexpression	FAN_OVARY_CL1_GPRC5A_TNFRS12A_HIGH_SELECTABLE_FOLLICLE_STROMAL_CELL	NOP56 NOP16 HNRNPA3 ENO1 HNRNPA2B1 HNRNPC	1.74e-04	380	57	6	M41703
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Glra3\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 MYH13 PEG3 GRM1 BAIAP3	7.94e-10	147	57	7	50e86860a94be103092c40e39a172eac92372f0d
ToppCell	mild-B_naive\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 PPFIBP1 SETBP1 SCN3A PELI1 MICAL3 ADARB1	6.76e-09	200	57	7	222789b897e2a683bbfd1d00b6fd8705015d90df
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Glra3\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 MYH13 PEG3 GRM1	5.75e-08	160	57	6	0bfdaf979e6f128cba2928ce16bca4d3deff8ac9
ToppCell	3'_v3-Lung-Lymphocytic_B-Memory_B_cells\|Lung / Manually curated celltypes from each tissue	CD22 SETBP1 SCN3A POU2F2 MICAL3 BAIAP3	8.53e-08	171	57	6	9ecef653f6916572bf5fbee5aea6c577d04e96ba
ToppCell	severe-B_memory\|World / disease stage, cell group and cell class	CD22 FAM227A PELI1 POU2F2 MICAL3 BAIAP3	1.01e-07	176	57	6	4e5c6b1aa5ffd13593a6bcd1e1253c1737c5c2b4
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A POU2F2 MICAL3 ADARB1	1.45e-07	187	57	6	d01926be1c8846a25fb6706e26b56b808b69f8f0
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A PELI1 MICAL3 ADARB1	1.49e-07	188	57	6	d8decd9b5967873ca8320c2f9f07365f163c777f
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_B-B_cell\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	DDAH1 CD22 SETBP1 SCN3A POU2F2 MICAL3	1.64e-07	191	57	6	2453064c39b359088d43d52792bf829f83442c82
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A PELI1 POU2F2 MICAL3	1.69e-07	192	57	6	446c61c0d6ba89c619efe87ee495951299953981
ToppCell	control-B_naive\|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SETBP1 SCN3A POU2F2 MICAL3 ADARB1	2.03e-07	198	57	6	c012b8fbfa8bbc5014217f47acf9177470d8a65a
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Ptgdr\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 MYH13 GRM1	5.70e-07	125	57	5	d05556ea185c15815a4f8643f1c01185badbeece
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Ptgdr\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 MYH13 GRM1	1.15e-06	144	57	5	71107275767a0728541a3695715c44874b3e5efc
ToppCell	Frontal_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Sst-Inhibitory_Neuron.Gad1Gad2.Sst-Nr2f2_(MGE-derived_cortical_interneurons--Martinotti_cells)\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	MYH1 MYH4 MYH8 MYH13	1.22e-06	62	57	4	a20620a8869721ea62984c2022ee1b484b455824
ToppCell	Frontal_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Sst-Inhibitory_Neuron.Gad1Gad2.Sst-Nr2f2_(MGE-derived_cortical_interneurons--Martinotti_cells)-\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	MYH1 MYH4 MYH8 MYH13	1.22e-06	62	57	4	ee694c06bcd924b4ddf744178ba3a99e04eed51b
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Myh8_Fibin\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 MYH13 BAIAP3	1.76e-06	157	57	5	741d79c10cb87fa7f14080c6fccb1553c3a20bad
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH4 MYH8 MYH13 GRM1 BAIAP3	1.99e-06	161	57	5	dccb61d5e17a8f1c6d1fc146ee389f567659a0f0
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 MYH13 GRM1	2.59e-06	170	57	5	8ab67e2b6e30fdf9e9a2c02e31d4df34e751a3ed
ToppCell	severe-B_memory\|severe / disease stage, cell group and cell class	CD22 FAM227A POU2F2 MICAL3 BAIAP3	2.83e-06	173	57	5	3a987ac53a0136cc4c70ce8b901a15fc00c795e1
ToppCell	Thalamus-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a7-Tac2-Excitatory_Neuron.Slc17a7.Tac2.Syt15_(Medial_habenula)\|Thalamus / BrainAtlas - Mouse McCarroll V32	MYH1 MYH2 MYH4 MYH13	2.92e-06	77	57	4	7f624e9262bd0dc2ac4176f43c91a4bc0f521fe5
ToppCell	Control-B_cells-B_cells\|Control / group, cell type (main and fine annotations)	CD22 PIK3CD SETBP1 POU2F2 MICAL3	3.07e-06	176	57	5	d2c353783bd78dc24f28e00d917b88d8294fb5df
ToppCell	COVID-19-lung-B_cells\|lung / Disease (COVID-19 only), tissue and cell type	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.16e-06	177	57	5	f54691e5558091c1734ab15153a10bff15ed171e
ToppCell	COVID-19-B_cells-Activated_B_cells\|COVID-19 / group, cell type (main and fine annotations)	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.16e-06	177	57	5	653bb62a3744d4024ab3186ee01d410ed62832a6
ToppCell	NS-moderate-d_16-33-Lymphoid-B_cell\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.16e-06	177	57	5	320fd77c7c98e9305dcc34a168ec9d674539ed65
ToppCell	CTRL-Lymphoid-B_cell\|CTRL / Disease state, Lineage and Cell class	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.34e-06	179	57	5	dd4055c0a8360ea10323ef6249519a6ae08fc05a
ToppCell	Severe-Lymphoid-B\|Severe / Condition, Lineage, Cell class and cell subclass	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.43e-06	180	57	5	67ffaf5096f025c3c61fffe52f6c8a96f120fc6f
ToppCell	3'_v3-Lung-Lymphocytic_B\|Lung / Manually curated celltypes from each tissue	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.43e-06	180	57	5	237a2130a3f48595dad2417539c21e44585962b8
ToppCell	Severe-Lymphoid-B-\|Severe / Condition, Lineage, Cell class and cell subclass	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.43e-06	180	57	5	fd3eb751704b14ff1500e4bd041441644d233e9c
ToppCell	PBMC-Convalescent-Lymphocyte-B-B_cell-B_naive-B_naive-1\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CD22 PPFIBP1 SCN3A POU2F2 MICAL3	3.52e-06	181	57	5	6df40f86c569b6ecfc3137a68d1355b012dbf6bf
ToppCell	normal-na-Lymphocytic_B-B_mem-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	CD22 SETBP1 PELI1 POU2F2 MICAL3	3.62e-06	182	57	5	ee36ea6cb9a5a08aeb83f2b7a249255f0b1a9870
ToppCell	Severe_COVID-19-B_cell-B_cell\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	CD22 SETBP1 SCN3A POU2F2 MICAL3	3.72e-06	183	57	5	5634e528001c389efd1e380f01ad40072f60e943
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 POU2F2 MICAL3 BAIAP3	4.02e-06	186	57	5	55b239834b96b1f7787ec77a7d19796d617bbbf0
ToppCell	BL-critical-LOC-Lymphoid-B_cell\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.02e-06	186	57	5	27d4c38b180e4ce2bf3e7c4ad3db3a2ffca05ca8
ToppCell	moderate-Lymphoid-B_cell\|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.02e-06	186	57	5	fd2c4c3e8929ca5d64f6c5064e5f3d3d6ba07b5f
ToppCell	IPF-Lymphoid-B\|Lymphoid / Disease state, Lineage and Cell class	CD22 SETBP1 PELI1 POU2F2 MICAL3	4.13e-06	187	57	5	af1327559f7e01bec070881cae52834917c3da65
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_memory-B_memory-0\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CD22 PELI1 POU2F2 MICAL3 BAIAP3	4.24e-06	188	57	5	229108e7e3db49e1cfd747d69e338394139d95b3
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	DDAH1 CD22 SETBP1 POU2F2 MICAL3	4.24e-06	188	57	5	5707786cc4452dc34f95db2b3cd29f6e025c0622
ToppCell	NS-moderate-d_07-13-Lymphoid-B_cell\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.24e-06	188	57	5	e9ed34cfea1d93eaa8e63d5b5dbb64f1520d9c4c
ToppCell	LA-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	MYH9 DDAH1 MICAL2 SCN3A ADARB1	4.35e-06	189	57	5	6b3e88751b95fc2173f2c3d5061ed632d0c5f01c
ToppCell	COVID-19_Severe-Lymphoid_B-B_memory\|COVID-19_Severe / Disease group, lineage and cell class	CD22 SETBP1 POU2F2 MICAL3 BAIAP3	4.46e-06	190	57	5	b6510c419a15ed049c0a0a6a6697b643668741c3
ToppCell	COVID_vent-Lymphocytic-B_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.46e-06	190	57	5	40b5e9e8f8fd8d84cb5b43e67b49267082348e9f
ToppCell	COVID_vent-Lymphocytic-B_cell-\|COVID_vent / Disease condition, Lineage, Cell class and subclass	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.46e-06	190	57	5	a37a32dc1b931562a6660074e19d5598efc65284
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-naive_B_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.46e-06	190	57	5	a7498fe55b7810c482291db782dc5282675d246a
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 PELI1 MICAL3 BAIAP3	4.46e-06	190	57	5	0db545a4cba7534bad2693e0d565cde7dbc7a586
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SCN3A PELI1 MICAL3 ADARB1	4.46e-06	190	57	5	0724665ac8238f2383c3a929d89abf4a48ec2420
ToppCell	COPD-Lymphoid-B\|Lymphoid / Disease state, Lineage and Cell class	CD22 SETBP1 PELI1 POU2F2 MICAL3	4.46e-06	190	57	5	1e85ee686ff6dd27c69415d524d54fa825b1daad
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_B\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.58e-06	191	57	5	a831e30f37aff329d83fac9bdb84f783075d5df6
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_B\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CD22 SCN3A POU2F2 MICAL3 HSPA4	4.58e-06	191	57	5	8dda37ebf74b587129795f61541cc511ec97a314
ToppCell	PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CD22 SETBP1 PELI1 POU2F2 MICAL3	4.58e-06	191	57	5	5a9a592875fbd0b1429b48db29a760fdc9c2c856
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-B_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.70e-06	192	57	5	0bda96d8f223e8fa9caf935079ab202fc5c812ee
ToppCell	moderate-Lymphoid-B_cell\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.70e-06	192	57	5	ae3727503c3b9f4695e565fd3161cc33b898f349
ToppCell	COVID_non-vent-Lymphocytic-B_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.82e-06	193	57	5	32d139f922cd19adc1cc1e0e9a828115be9945d6
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 POU2F2 MICAL3 BAIAP3	4.82e-06	193	57	5	de0213f2105b814f38ffbfd004ea7603230eed68
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_B\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.82e-06	193	57	5	6e6c5ae39ea880ba809019a7d39f50e4e02007ed
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_B-B_cell\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.82e-06	193	57	5	c04ac5884be4245b75d211046f04d76ae0cfb998
ToppCell	COVID_non-vent-Lymphocytic-B_cell-\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	CD22 SETBP1 SCN3A POU2F2 MICAL3	4.82e-06	193	57	5	91955c3773c9729a96e82f240f06b072367970d9
ToppCell	severe-B_cell\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	ARHGEF33 CD22 SCN3A RHBDL1 HSPA4	4.94e-06	194	57	5	2fee6083fb56b16d1f04fd0b92ec622fd26ba3fa
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_B-B_naive-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CD22 SCN3A POU2F2 MICAL3 HSPA4	4.94e-06	194	57	5	83554ba6a789750a39af58537fd7044ce20d3f02
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_B-B_naive\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CD22 SCN3A POU2F2 MICAL3 HSPA4	4.94e-06	194	57	5	56286db641cfb270e52f33989b8bf7b14d45010a
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	DDAH1 CD22 SETBP1 SCN3A POU2F2	4.94e-06	194	57	5	cbc4b6422777117e4123804168c23f19d1b79486
ToppCell	E12.5\|World / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	NOP56 HNRNPA3 ENO1 HNRNPA2B1 HNRNPC	4.94e-06	194	57	5	4b335e4da58de1cd94194dc4208ce83854e5e50a
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CD22 SETBP1 SCN3A PELI1 MICAL3	5.07e-06	195	57	5	0c49d22c348aec6d8a1a976e7c88d0a3b48a4244
ToppCell	severe-B_cell\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	ARHGEF33 CD22 SCN3A RHBDL1 POU2F2	5.07e-06	195	57	5	0fc3c605609c9e6bdea15d73c45def2188ae5fb1
ToppCell	Control-Classical_Monocyte-cMono_2\|Classical_Monocyte / Disease condition and Cell class	MYH9 BCLAF1 HNRNPA3 POU2F2 HNRNPA2B1	5.32e-06	197	57	5	eb7610c9496a95a5fd866e16abcbc39b83abe617
ToppCell	COVID-19_Severe-Lymphoid_B\|COVID-19_Severe / Disease group, lineage and cell class	CD22 SETBP1 SCN3A POU2F2 MICAL3	5.32e-06	197	57	5	25303329b051831cf2ed4df68f3948308e5fbd96
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CD22 SETBP1 SCN3A POU2F2 MICAL3	5.32e-06	197	57	5	5c67ed18fb92aec73c79f4db6d80cec777d9ba44
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MICAL2 ICA1 SETBP1 SCN3A PEG3	5.46e-06	198	57	5	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MICAL2 ICA1 SETBP1 SCN3A PEG3	5.46e-06	198	57	5	4ca5ff320905ab4ff60ed90a5522227c782142a6
ToppCell	mild-B_memory\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SETBP1 PELI1 MICAL3 BAIAP3	5.59e-06	199	57	5	e6ac9a0959b0de2c6a99298feb7715aa80ade1dd
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-B-B_memory\|COVID-19_Severe / Disease, condition lineage and cell class	CD22 SETBP1 POU2F2 MICAL3 BAIAP3	5.59e-06	199	57	5	24c05faa825c9d55279956469862440f9914a280
ToppCell	severe-B_memory\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SETBP1 POU2F2 MICAL3 BAIAP3	5.59e-06	199	57	5	6d3436dd65d525aaa23ec02672005380f21c4d0f
ToppCell	mild-B_intermediate\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SETBP1 PELI1 POU2F2 MICAL3	5.73e-06	200	57	5	fe815824e9e4be3f3db73610e3814a7fd533da65
ToppCell	severe-B_naive\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SETBP1 SCN3A PELI1 MICAL3	5.73e-06	200	57	5	0e86f52b6e146d9bbc728d8fb176fc2b53696558
ToppCell	mild-B_intermediate\|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SETBP1 PELI1 POU2F2 MICAL3	5.73e-06	200	57	5	8e3132a1fe3708f725c5c4077878fb87bbea3678
ToppCell	severe\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	MYH9 BCLAF1 HNRNPA3 HNRNPA2B1 HNRNPC	5.73e-06	200	57	5	accc618d6b960bff30cb531c1226295bfc8650f6
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	MYH9 BCLAF1 HNRNPA3 HNRNPA2B1 STAT1	5.73e-06	200	57	5	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	severe-B_naive\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CD22 SCN3A PELI1 POU2F2 MICAL3	5.73e-06	200	57	5	306df1f498ac2188eaf9f2a8d002bb73bdb9642d
ToppCell	Control-Control-Lymphocyte-B-B_naive\|Control / Disease, condition lineage and cell class	CD22 SCN3A POU2F2 MICAL3 ADARB1	5.73e-06	200	57	5	15e4b9956b9a0c2e6927a802e86e1cb4bb18b89a
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Myh8_Etv1_\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 GRM1	7.35e-06	97	57	4	f3c3fb260954f594a9ab8e1ac9a01115767cbc7a
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Tac2_Myh4\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 GRM1	2.26e-05	129	57	4	f83187c0bb06528127b8d2d56674ab1946846951
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Esm1\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 GRM1	2.41e-05	131	57	4	3cb4b272e28ee9bad6d874f64a7aae18352a6cfb
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	DDAH1 CD22 SETBP1 POU2F2	3.30e-05	142	57	4	66135fee18448cc09a78bc6ede05afd63c72ae21
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Myh8_Etv1_\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 MYH8 GRM1	3.88e-05	148	57	4	4d43efee96a6493abd78e9ca41aab73db0c80626
ToppCell	3'_v3-Lung-Lymphocytic_B-Naive_B_cells\|Lung / Manually curated celltypes from each tissue	CD22 SCN3A POU2F2 MICAL3	4.53e-05	154	57	4	2b7d7f09c75bbc22de1358fc44b8ad5d3f656617
ToppCell	PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-10\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MYH2 CD22 SETBP1 POU2F2	4.76e-05	156	57	4	d81e78bec5c8a3f3ec9e1447ebab2c5805b815eb
ToppCell	Severe-B_naive-1\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	MYH9 CD22 PIK3CD SCN3A	5.13e-05	159	57	4	2881b054bbeb479221ee3c38bbd9b0815b123579
ToppCell	RV-13._Vascular_Smooth_Muscle\|World / Chamber and Cluster_Paper	DDAH1 CD22 SCN3A DGKH	5.25e-05	160	57	4	29c9b4770d0e73d59cffc7937b179484c76b6dcc
ToppCell	RV-13._Vascular_Smooth_Muscle\|RV / Chamber and Cluster_Paper	DDAH1 CD22 SCN3A DGKH	5.38e-05	161	57	4	47b3b7662cbb671ccc086dc0a0cabd65f63eb5a1
ToppCell	PND03-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B-B-B_G2M\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ESCO2 CDCA2 CD22 ARHGEF1	5.78e-05	164	57	4	249d8f75a64bce7db52ce0c563f496b9edf602a6
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYH1 MYH2 MYH4 MYH8	5.78e-05	164	57	4	382e42701779d12a7948690b3be72d06dd75c8b4
ToppCell	normal-na-Lymphocytic_B-B_atypical-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	CD22 LPGAT1 POU2F2 ADARB1	6.06e-05	166	57	4	30a180b67572c3f4fb3a291f271f855e1b20005e
ToppCell	facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l44-58\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MYH1 MYH4 MYH8 FAM83C	6.20e-05	167	57	4	d78356bf0c473816dbabaee51984940bd822f84e
ToppCell	Control-B_cells-Activated_B_cells\|Control / group, cell type (main and fine annotations)	CD22 SETBP1 POU2F2 MICAL3	6.35e-05	168	57	4	a7159a35fe37f8c241cf8d391debe271e0698105
ToppCell	Children_(3_yrs)-Immune-B_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	CD22 SETBP1 POU2F2 MICAL3	6.65e-05	170	57	4	e421f9eedf74baffda1d03707a710ece4b777f29
ToppCell	Adult-Immune-B_cell-D175\|Adult / Lineage, Cell type, age group and donor	CD22 SETBP1 POU2F2 MICAL3	6.80e-05	171	57	4	355a246f3395900342d400f6f7c6640cba0d4d5d
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Sst-Inhibitory_Neuron.Gad1Gad2.Sst-Nr2f2_(Neuron.Gad1Gad2.Sst-Nr2f2)-\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	MYH4 MYH8 MYH13	6.91e-05	62	57	3	9db88da996b9977f5a89afe505cd55e7b5324bc9
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Sst-Inhibitory_Neuron.Gad1Gad2.Sst-Nr2f2_(Neuron.Gad1Gad2.Sst-Nr2f2)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	MYH4 MYH8 MYH13	6.91e-05	62	57	3	461d280a1b955033186cfc326f9ace85b4a53c54
ToppCell	severe_influenza-B_memory\|World / disease group, cell group and cell class (v2)	SLC15A1 CD22 MICAL3 BAIAP3	6.96e-05	172	57	4	0ff38f9431cec73250c580a6010cb7891a3fe3f1
ToppCell	PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-4\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CD22 SCN3A PELI1 MICAL3	6.96e-05	172	57	4	62ed3b70fa1f6c84ea80ff00f60d2562be292e9d
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ESCO2 CDCA2 PIK3CD POU2F2	6.96e-05	172	57	4	ef33b5e0515c6d29fb6d9a673011c1b68ef264f3
ToppCell	368C-Lymphocytic-CD4_T-cell-Treg_cell_1\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	MICAL2 ICA1 DGKH PLOD1	7.11e-05	173	57	4	efb8072475000888efe088d00e870c56ffad4172
Drug	formycin triphosphate	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	4.47e-11	51	57	7	CID000122274
Drug	purealin	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.15e-10	58	57	7	CID006419303
Drug	S-(-)-Etomoxir	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 CPT1C MYO15A	1.44e-10	100	57	8	CID000060765
Drug	blebbistatin	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 RHBDL1 MYO15A	4.77e-10	116	57	8	CID003476986
Drug	clenbuterol	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A	2.40e-09	142	57	8	CID000002783
Drug	B0683	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.69e-08	117	57	7	CID006398969
Drug	fast white	MYH1 MYH2 MYH4 MYH8 MYH13	6.51e-08	42	57	5	CID000024008
Drug	carvedilol	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 NR1H4	1.52e-07	161	57	7	CID000002585
Drug	NSC611747	MYH1 MYH2 MYH4 MYH8 MYH13 BCLAF1 SETBP1 GRM1 MYO15A	2.13e-07	352	57	9	CID000002534
Drug	D-triiodothyronine	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 BCLAF1 ENO1 NR1H4	7.49e-07	409	57	9	CID000000861
Drug	AC1LADJ6	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	8.82e-07	130	57	6	CID000486032
Drug	candesartan cilexetil	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13	1.67e-06	145	57	6	CID000002540
Drug	SM-2	MYH1 MYH2 MYH4 MYH8 MYH13	2.60e-06	87	57	5	CID000486033
Drug	NSC339663	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	2.93e-06	250	57	7	CID000003892
Drug	eye gene	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A HSPA4	3.65e-06	369	57	8	CID000004782
Drug	Cefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; PC3; HT_HG-U133A	MAGI1 MYH2 CD22 PIK3CD ICA1 GRM1	9.77e-06	197	57	6	3686_UP
Drug	Corynanthine hydrochloride [66634-44-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A	PIK3CD ICA1 SETBP1 GRM1 ADARB1 BAIAP3	1.01e-05	198	57	6	4811_UP
Drug	AC1L1IZ2	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.05e-05	304	57	7	CID000004795
Drug	Flurbiprofen [5104-49-4]; Up 200; 16.4uM; MCF7; HT_HG-U133A	CD22 ARHGEF1 ICA1 GRM1 ADARB1 NR1H4	1.07e-05	200	57	6	5634_UP
Drug	NSC107658	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.10e-05	306	57	7	CID000002919
Drug	4-chloroaniline	MYH1 MYH2 MYH4 MYH8 MYH13 RHBDL1	1.13e-05	202	57	6	CID000007812
Drug	oxovanadium	MYH1 MYH2 MYH4 MYH8 MYH13	1.26e-05	120	57	5	CID000024411
Drug	2bq7	MYH1 MYH2 MYH4 MYH8 MYH13	1.42e-05	123	57	5	CID006540267
Drug	LY294002	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 PIK3CD POU2F2 HSPA4 STAT1	1.47e-05	748	57	10	CID000003973
Drug	trifluoperazine	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	1.59e-05	324	57	7	CID000005566
Drug	AC1NRBPQ	MYH1 MYH2 MYH4 MYH8 MYH13	2.39e-05	137	57	5	CID005288569
Drug	MgCl2	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A	2.81e-05	354	57	7	CID000024584
Drug	verapamil	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 KCNK15 SCN3A	2.85e-05	490	57	8	CID000002520
Drug	wartmannin	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 PIK3CD MYO15A HSPA4 STAT1	2.95e-05	811	57	10	CID000005691
Drug	AC1N9ZZC	MYH1 MYH2 MYH4 MYH8 MYH13	3.57e-05	149	57	5	CID004369374
Drug	N-ethylmaleimide	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A HSPA4	3.83e-05	511	57	8	CID000004362
Drug	isoproterenol	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 SCN3A MYO15A HNRNPA2B1	3.95e-05	669	57	9	CID000003779
Drug	AC1L1AUZ	ESCO2 HNRNPA3 ADARB1 HNRNPA2B1 HNRNPC	4.59e-05	157	57	5	CID000001160
Drug	AC1NOOVE	ESCO2 CD22	6.13e-05	5	57	2	CID005116706
Drug	nifedipine	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 GRM1	7.66e-05	415	57	7	CID000004485
Drug	Rescinnamin [24815-24-5]; Up 200; 6.4uM; MCF7; HT_HG-U133A	CD22 PIK3CD ICA1 MYO15A STAT1	9.00e-05	181	57	5	2785_UP
Drug	creatine	MYH1 MYH2 MYH4 MYH8 MYH13	1.22e-04	193	57	5	CID000000586
Drug	PHA-00851261E [724719-49-7]; Down 200; 1uM; PC3; HT_HG-U133A	MICAL2 ARHGEF1 SETBP1 ADARB1 STAT1	1.28e-04	195	57	5	4333_DN
Drug	NSC226080	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 PIK3CD HSPA4 STAT1	1.30e-04	782	57	9	CID000005040
Drug	Letrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A	BBS7 GRM1 ENO1 HSPA4 STAT1	1.31e-04	196	57	5	4824_UP
Drug	sulfasalazine; Down 200; 100uM; MCF7; HG-U133A	PPFIBP1 ICA1 GTPBP1 ADARB1 HSPA4	1.31e-04	196	57	5	204_DN
Drug	Cetirizine dihydrochloride [83881-52-1]; Up 200; 8.6uM; MCF7; HT_HG-U133A	MICAL2 ICA1 SETBP1 GRM1 ADARB1	1.34e-04	197	57	5	4815_UP
Drug	Pivampicillin [33817-20-8]; Up 200; 8.6uM; PC3; HT_HG-U133A	PIK3CD ICA1 POU2F2 GRM1 ADARB1	1.34e-04	197	57	5	5046_UP
Drug	Orlistat; Up 200; 10uM; MCF7; HT_HG-U133A	SLC15A1 ICA1 POU2F2 GRM1 MYO15A	1.34e-04	197	57	5	6383_UP
Drug	Etofylline [519-37-9]; Up 200; 17.8uM; MCF7; HT_HG-U133A	MYH2 CD22 VILL PIK3CD BAIAP3	1.37e-04	198	57	5	2256_UP
Drug	Pivmecillinam hydrochloride [32887-03-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A	SLC15A1 ICA1 MYO15A ADARB1 BAIAP3	1.37e-04	198	57	5	6014_UP
Drug	0316684-0000 [391209-55-5]; Down 200; 10uM; MCF7; HT_HG-U133A	MAGI1 ICA1 ENO1 HSPA4 STAT1	1.37e-04	198	57	5	7093_DN
Drug	Guanfacine hydrochloride [29110-48-3]; Up 200; 14.2uM; MCF7; HT_HG-U133A	MAGI1 ARHGEF1 ICA1 ADARB1 BAIAP3	1.37e-04	198	57	5	2634_UP
Drug	Lymecycline [992-21-2]; Up 200; 6.6uM; MCF7; HT_HG-U133A	RHBDL1 POU2F2 GRM1 MYO15A ADARB1	1.40e-04	199	57	5	5994_UP
Drug	Tacrine hydrochloride hydrate [1684-40-8]; Up 200; 15.8uM; MCF7; HT_HG-U133A	SLC15A1 PIK3CD ARHGEF1 POU2F2 ADARB1	1.44e-04	200	57	5	2633_UP
Drug	blebbistatin	MYH2 MYH9	1.71e-04	8	57	2	ctd:C472645
Drug	2,3,5,6-tetrafluoro-4-methylbenzyl (Z)-(1RS)-cis-3-(2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate	SCN3A NR1H4	1.71e-04	8	57	2	ctd:C489827
Drug	nocodazole	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 HSPA4	1.81e-04	477	57	7	CID000004122
Drug	AC1NDQQF	MYH1 MYH2 HSPA4	2.09e-04	46	57	3	CID004630071
Drug	pyrophosphate	MYH1 MYH2 MYH4 MYH8 MYH9 MYH13 MYO15A POLR3A	2.12e-04	654	57	8	CID000001023
Drug	I-Pb	PLOD1 HSPA4	2.19e-04	9	57	2	CID003431293
Drug	glycerol-3-phosphate	ESCO2 CPT1C LPGAT1 GTPBP1 ENO1	2.54e-04	226	57	5	CID000000754
Disease	myopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13 HNRNPA3 HNRNPA2B1	3.65e-12	48	55	7	DOID:423 (implicated_via_orthology)
Disease	dilated cardiomyopathy 1S (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0110454 (implicated_via_orthology)
Disease	autosomal dominant hyaline body myopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0111269 (implicated_via_orthology)
Disease	congenital myopathy 6 (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0080719 (implicated_via_orthology)
Disease	distal arthrogryposis type 2B3 (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0111602 (implicated_via_orthology)
Disease	inclusion body myositis (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:3429 (implicated_via_orthology)
Disease	distal arthrogryposis type 2A (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0111605 (implicated_via_orthology)
Disease	familial hypertrophic cardiomyopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0080326 (implicated_via_orthology)
Disease	distal arthrogryposis type 1 (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.67e-12	10	55	5	DOID:0111596 (implicated_via_orthology)
Disease	distal myopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	1.46e-11	12	55	5	DOID:11720 (implicated_via_orthology)
Disease	myotonia congenita (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	1.46e-11	12	55	5	DOID:2106 (implicated_via_orthology)
Disease	restrictive cardiomyopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	2.38e-11	13	55	5	DOID:397 (implicated_via_orthology)
Disease	distal arthrogryposis (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	5.53e-11	15	55	5	DOID:0050646 (implicated_via_orthology)
Disease	cardiomyopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	2.21e-07	71	55	5	DOID:0050700 (implicated_via_orthology)
Disease	dilated cardiomyopathy (implicated_via_orthology)	MYH1 MYH2 MYH4 MYH8 MYH13	4.04e-07	80	55	5	DOID:12930 (implicated_via_orthology)
Disease	obesity (implicated_via_orthology)	SLC15A1 PUM2 HSD17B4 ADARB1 STAT1	5.07e-05	215	55	5	DOID:9970 (implicated_via_orthology)
Disease	hearing impairment	HSD17B4 MYO15A STAT1	8.22e-04	98	55	3	C1384666
Disease	JT interval, response to sulfonylurea	HSD17B4 STAT1	8.42e-04	23	55	2	EFO_0007885, EFO_0007922
Disease	C-reactive protein measurement	MYH2 FAM227A MICAL3 DGKH GTPBP1 ADARB1 HNRNPC NR1H4	1.68e-03	1206	55	8	EFO_0004458
Disease	sensorineural hearing loss (is_implicated_in)	MYH9 MYO15A	1.74e-03	33	55	2	DOID:10003 (is_implicated_in)
Disease	Spinocerebellar Ataxia Type 2	NOP56 GRM1	1.84e-03	34	55	2	C0752121
Disease	Spinocerebellar Ataxia Type 1	NOP56 GRM1	1.84e-03	34	55	2	C0752120
Disease	Spinocerebellar Ataxia Type 5	NOP56 GRM1	1.84e-03	34	55	2	C0752123
Disease	Spinocerebellar Ataxia Type 7	NOP56 GRM1	1.84e-03	34	55	2	C0752125
Disease	Spinocerebellar Ataxia Type 6 (disorder)	NOP56 GRM1	1.84e-03	34	55	2	C0752124
Disease	Ataxia, Spinocerebellar	NOP56 GRM1	1.84e-03	34	55	2	C0087012

Protein segments in the cluster

Peptide	Gene	Start	Entry
REFSLFAGKRAFSQK	FAM227A	321	F5H4B4
AASEIRGFTKRGKQF	BBS7	86	Q8IWZ6
RGFTKRGKQFLSFET	BBS7	91	Q8IWZ6
GRNFFRKKVMGNRRS	ARHGEF1	241	Q92888
AQKEQRFGFRKGSKR	BAIAP3	236	O94812
DNGRGFARQKLFRHK	GTPBP1	186	O00178
QDQKGGFRSSFRKLF	ARHGEF33	811	A8MVX0
SRRRKAQFFLGTTNK	ARMC1	126	Q9NVT9
KLDSRFRKGNFGTRD	PUM2	106	Q8TB72
GCKGFFRRSITKNAV	NR1H4	156	Q96RI1
FIGRAAAKNKGRISR	NOP56	356	O00567
RNTLEGFRRKEFRGK	MICAL3	226	Q7RTP6
SRRGKSGFNSKSGQR	HNRNPC	166	P07910
GFLRKRRETSQAFAK	LPGAT1	186	Q92604
AVTFKAVRQGGRLNK	MAGI1	96	Q96QZ7
KNTVQGFKRFHGRAF	HSPA4	61	P34932
RKAKSQNRQATFSGR	MGA	896	Q8IWI9
VRSSFGRGFFKIKSN	PPFIBP1	521	Q86W92
KTVRNDNSSRFGKFV	MYO15A	1361	Q9UKN7
LVQKRGALRRKFGFS	KCNK15	41	Q9H427
AKTVRNDNSSRFGKF	MYH8	236	P13535
AKTVRNDNSSRFGKF	MYH2	236	Q9UKX2
FARTFKQRRIKLGFT	POU2F2	206	P09086
AKTVRNDNSSRFGKF	MYH1	236	P12882
TVKNDNSSRFGKFIR	MYH9	226	P35579
SGDNQGVKFLRRFKQ	DGKH	341	Q86XP1
FGRKRRKSRTAFTAQ	LBX2	81	Q6XYB7
QKRSIFQKSERGGFR	ADARB1	421	P78563
FRGGFRFNSTLVSRK	PEG3	371	Q9GZU2
KETEGFRRFKRSAQF	PLOD1	36	Q02809
QHFKRRFRGSGKENS	CPT1C	766	Q8TCG5
ELGSKAKFAGRNFRN	ENO1	416	P06733
SKAGRRFTGQALEKF	FAM83C	241	Q9BQN1
QKAFFSGRLKARGNI	HSD17B4	706	P51659
RGTFQRGRGRFNFKK	BCLAF1	866	Q9NYF8
QGGAAFFVRKKSSLR	ESCO2	206	Q56NI9
QFKGYRRRSSLNGKG	CDCA2	991	Q69YH5
TFLNIFRRKKAGAGN	GRM1	871	Q13255
GFAIKNRFRHRSKAF	SLC15A1	241	P46059
REFFVGLSKRTNQRG	DDAH1	136	O94760
SGQSFFVRNKKVRRA	CD22	726	P20273
RNTLEGFRRKEFRGK	MICAL2	226	O94851
NGDRGRRKSRFALFK	PELI1	31	Q96FA3
KFLRSQGFQDKTRAG	ICA1	96	Q05084
KKRVNTRFFAQSGGR	PIWIL1	741	Q96J94
RNTVKGFRKFNILGT	STAT1	371	P42224
DGKNRLQGFKARFTI	OVCH1	516	Q7RTY7
FVQRLKGKQGRFRGN	POLR3A	341	O14802
AKTVRNDNSSRFGKF	MYH4	236	Q9Y623
RNSKTSIFSFRGRAK	SCN3A	571	Q9NY46
GKTRRQKFGYSVNRK	NOP16	6	Q9Y3C1
KRSSSFKRAIANGQR	RHBDL1	136	O75783
DRQSGKKRGFGFVTF	HNRNPA2B1	146	P22626
KTVRNDNSSRFGKFI	MYH13	236	Q9UKX3
LGNFKTKFGINRERV	PIK3CD	916	O00329
RQSGKKRGFAFVTFD	HNRNPA3	161	P51991
RKAAFSRAVGFIQAK	VILL	306	O15195
RQSKTGNNFVKKRRG	SETBP1	1441	Q9Y6X0